Amyloid Imaging
part of the Molecular Imaging Resident Training Series

August 2, 2012 | 2:00pm ET | Register

This presentation will provide a basic introduction to amyloid and amyloid-related disorders with an emphasis on non-cerebral amyloidosis and show examples of clinical and pre-clinical methods for detecting this pathology by using molecular imaging techniques. The presentation will focus on basic scientific aspects of amyloid structure, amyloid imaging and strategies for developing amyloid-targeting biomolecules. This seminar will be of interest to those keen to better understand the broad nature of amyloid diseases and the strategies used to image this pathology. At the end of the presentation the attendee will better appreciate the role of amyloid in many diseases states and the numerous methods that are being employed to develop radiotracers for imaging amyloidosis.

Learning Objectives:

1. Provide a description of the structure of amyloid and discuss the numerous diseases associated with amyloid deposition.

2. Review the numerous radiotracers used for detecting amyloid by molecular imaging in both the preclinical and clinical arenas.

3. Describe strategies for developing an effective radiotracer for imaging amyloid in visceral organs and how these tracers can be evaluated.

4. Discuss the various types of amyloid and amyloid imaging techniques and describe the relevance of imaging this pathology in multiple disease states.

About the Presenter:

Jonathan Wall is a tenured Professor in the Human Immunology and Cancer Program at the University of Tennessee Graduate School of Medicine, Knoxville, TN. He joined the HICP in 1995 and has studied biochemical and biophysical aspects of visceral amyloidosis. His work has led to a “first-in-human” clinical trial studying the biodistribution, by using PET/CT imaging, of a novel radio-iodinated amyloid fibril-reactive antibody in patients with light chain amyloidosis. He leads an NIH-funded, multidisciplinary team of researchers focused on developing novel therapeutic and molecular imaging agents for amyloid disease, type 2 diabetes, and cancer. Dr. Wall is director of the Preclinical and Diagnostic Molecular Imaging Program at the University of Tennessee Graduate School of Medicine.